CREB1-BCL2 Drives Mitochondrial Resilience in RAS GAP-Dependent Breast Cancer Chemoresistance

Researchers showed that RASAL2 was enriched following neoadjuvant chemotherapy in triple-negative breast cancer patients. This enrichment was specific to the tumor compartment compared to adjacent normal tissues, suggesting that RASAL2 upregulation is tumor-selective.